These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 16018827

  • 1. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH.
    Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
    [Abstract] [Full Text] [Related]

  • 2. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 4. [Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis].
    van der Kwast TH, Hoedemaeker RF, Schröder FH.
    Ned Tijdschr Geneeskd; 2005 Apr 30; 149(18):972-6. PubMed ID: 15903037
    [Abstract] [Full Text] [Related]

  • 5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May 30; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R, Roobol M, Schröder FH, van der Kwast TH.
    Cancer; 2004 Mar 01; 100(5):968-75. PubMed ID: 14983492
    [Abstract] [Full Text] [Related]

  • 8. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul 01; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 9. Lesions predictive for prostate cancer in a screened population: first and second screening round findings.
    Postma R, Roobol M, Schröder FH, van der Kwast TH.
    Prostate; 2004 Nov 01; 61(3):260-6. PubMed ID: 15368469
    [Abstract] [Full Text] [Related]

  • 10. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
    Postma R, Schröder FH, van der Kwast TH.
    Urology; 2005 Apr 01; 65(4):745-9. PubMed ID: 15833520
    [Abstract] [Full Text] [Related]

  • 11. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb 01; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 12. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population.
    Gokden N, Roehl KA, Catalona WJ, Humphrey PA.
    Urology; 2005 Mar 01; 65(3):538-42. PubMed ID: 15780372
    [Abstract] [Full Text] [Related]

  • 13. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ, Grenabo A, Schröder FH, Hugosson J.
    J Natl Cancer Inst; 2007 Sep 05; 99(17):1296-303. PubMed ID: 17728218
    [Abstract] [Full Text] [Related]

  • 14. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 05; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 15. Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology.
    Hautmann SH, Conrad S, Henke RP, Erbersdobler A, Simon J, Straub M, Graefen M, Hautmann RE, Huland H.
    J Urol; 2000 Jun 05; 163(6):1734-8. PubMed ID: 10799171
    [Abstract] [Full Text] [Related]

  • 16. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care.
    Epstein JI, Herawi M.
    J Urol; 2006 Mar 05; 175(3 Pt 1):820-34. PubMed ID: 16469560
    [Abstract] [Full Text] [Related]

  • 17. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
    Djavan B, Fong YK, Ravery V, Remzi M, Horninger W, Susani M, Kreuzer S, Boccon-Gibod L, Bartsch G, Marberger M.
    Eur Urol; 2005 Jan 05; 47(1):38-44; discussion 44. PubMed ID: 15582247
    [Abstract] [Full Text] [Related]

  • 18. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E.
    J Urol; 2003 May 05; 169(5):1720-3. PubMed ID: 12686817
    [Abstract] [Full Text] [Related]

  • 19. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
    Naya Y, Ayala AG, Tamboli P, Babaian RJ.
    Urology; 2004 Mar 05; 63(3):503-8. PubMed ID: 15028446
    [Abstract] [Full Text] [Related]

  • 20. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK.
    BJU Int; 2007 Apr 05; 99(4):775-9. PubMed ID: 17223921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.